Raxibacumab

mAbs

Volumn 1, Issue 6, 2009, Pages 531-538

  Mazumdar, Sohini ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal rule; Anthrax; Anti PA; Bioterrorism; Monoclonal antibody; Raxibacumab

Indexed keywords

ABTHRAX; CIPROFLOXACIN; MONOCLONAL ANTIBODY; RAXIBACUMAB; UNCLASSIFIED DRUG;

ANTHRAX; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; HUMAN; IN VITRO STUDY; NONHUMAN; SHORT SURVEY;

ANIMALS; ANTHRAX; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOTERRORISM; DEVICE APPROVAL; HUMANS; UNITED STATES;

EID: 77953667961     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.6.10195     Document Type: Short Survey

References (16)

1. Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5:191-195 (Pubitemid 43336032)
2. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-2252
3. Schneemann A, Manchester M. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol 2009; 4:35-43.
4. Zmuda JF, Zhang L, Sosnovtseva S, Bukreyeva N, Beebe L, Hunt R, et al. Detection of host-derived neutralizing antibodies against anthrax protective antigen (PA) in PAmAb-treated monkeys surviving lethal spore challenge: relationship to secondary exposure immunity. American Society of Microbiology Biodefense Meeting, 2004; Abstract 65H. http://www.hgsi.com/images/pdf/asm- monkey-rechallenge.pdf.
5. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-144
6. Federal Register. New drugs and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register 2002; 67:37988-37998
7. Project BioShield Act of 2004 (P.L. 108-276). http://www.hhs.gov/aspr/ barda/bioshield/index.html.
8. Russell PK. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis 2007; 45:68-72.
9. Zhang X, Askins J, Fleming R, Sturm B, Poortman C, Viriassov P, et al. Selection of potent neutralizing human monoclonal antibodies to protective antigen of Bacillus anthracis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003; Abstract 3976. http://www.hgsi.com/images/pdf/ icaac.pdf.
10. Kahn DW. Development and characterization of a scalable purification process for ABThraxTM. American Society of Microbiology Biodefense Meeting. 2004; http://www.hgsi.com/images/pdf/asm-kahn.ppt.
11. Luo R, Waghmare R, Krishnan M, Adams C, Poon E, Kahn D. High-concentration UF/DF of a monoclonal antibody: strategy for optimization and scale-up. BioProcess Int 2006; 4:44-47
12. Cui X, Li Y, Moayeri M, Choi GH, Subramanian GM, Li X, et al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005; 191:422-434 (Pubitemid 40139768)
13. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003; Abstract 3836. http://www.hgsi.com/images/pdf/icaacpamab.pdf.
14. Beebe L, Babin M, Barnewall R, Zhong J, Choi G. Post-exposure therapeutic potential of PAmAb in an inhalation model of anthrax in New Zealand white rabbits. American Society of Microbiology Biodefense Meeting, 2004; Abstract 167G. http://www.hgsi.com/images/pdf/asm-beebe.pdf.
15. Subramanian GM, Cronin PW, Poley G, Weinstein A, Stoughton SM, Zhong J, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41:12-20.
16. Nabel GJ. Protecting against future shock-inhalational anthrax. N Engl J Med 2009; 361:191-193